Phio advances Phase 1b skin cancer trial to 5th cohort; presents at conference

Phio Pharmaceuticals Corp.

Patients are now being treated in the 5th cohort of the ongoing Phase 1b clinical trial for skin cancer (PH-762).
Phio Pharmaceuticals will present at H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025.
CEO Robert Bitterman will deliver an update on the trial and discuss strategy and next steps for the PH-762 program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.